Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to ...

Parmod Sagar, Chairman and Managing Director of RHI Magnesita, stated that the company aims to achieve 15% margins by second ...